Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01361685 · ClinicalTrials.gov registry record
Model 4396 Left Ventricular (LV) Lead Chronic Performance Study
A clinical trial, sponsored by Medtronic.
- Completed
- Registry status
- 366
- Enrollment target
NCT01361685: Completed study, sponsored by Medtronic.
NCT01361685 is a clinical trial that has completed, run by Medtronic. The registered enrollment target is 366 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01361685 has completed, sponsored by Medtronic.
- COMPLETED
- Registry status
- 366 participants
- Enrollment target
Study Summary
Lead survivability will be summarized.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2011-05 |
| Est. Completion | 2021-02-04 |
What the finished NCT01361685 record still lists
NCT01361685 is an observational study that tracks outcomes without assigning an intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01361685 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01361685 about?
NCT01361685 is a clinical study titled "Model 4396 Left Ventricular (LV) Lead Chronic Performance Study". Lead survivability will be summarized.
What is the current status of trial NCT01361685?
This trial is currently completed. The enrollment target is 366 participants. The study started on 2011-05. Estimated completion is 2021-02-04.
Who is sponsoring clinical trial NCT01361685?
This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia